Pharmacist Review Flags Drug Problems in CKD Patients Starting SGLT2 Inhibitors
A single-center observational study describing the feasibility of clinical pharmacist-led medication review and nephrotoxic burden assessment in nephrology outpatients newly started on sodium-glucose cotransporter 2 inhibitors.
📅 Journal publication: Dec 2026(online Jun 23, 2026)·Last updated: Jul 29, 2026
Pharmacist interventions reduce drug problems in CKD patients on SGLT2 inhibitors.
CKD patients often face medication burdens which can increase nephrotoxicity risks, impacting their health outcomes. In 72 patients, 69 drug-related problems were identified, with high acceptance (85.5%) of pharmacist recommendations. No overt nephrotoxic events were observed. This study highlights the importance of pharmacist-led reviews in managing polypharmacy and reducing nephrotoxic risks in CKD patients. However, further studies are needed for definitive conclusions. Pharmacist-led medication reviews reduce drug-related problems in CKD patients on SGLT2 inhibitors without observed nephrotoxic events.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Ozturk Yalcin Z, Erdut A, Haberal G, Arici M, Bayraktar-Ekincioglu A
Citation:Ozturk Yalcin Z, Erdut A, Haberal G, et al. Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors. Renal failure. 2026;48(1):2688512. doi:10.1080/0886022X.2026.2688512